MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients

Rinaldi, Federica; Marchesi, Francesco; Palombi, Francesca; Pelosi, Andrea; Pace, Anna; Sacconi, Andrea; Terrenato, Irene; Annibali, Ombretta; Tomarchio, Valeria; Marino, Mirella; Cantonetti, Maria; Vaccarini, Sara; Papa, Elena; Moretta, Lorenzo; Bertoni, Francesco; Mengarelli, Andrea; Regazzo, Giulia; Rizzo, Maria Giulia

doi:10.1111/bjh.17734

Cited by 7 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in concordance with a previous study in which extracellular mRNA of CCND2, BCL2, MYC, LMO2, and BCL6 was detected in only 14%, 10%, 10%, 10%, and 5% of DLBCL plasma samples, respectively, but in all of the matched tissue samples (40). Similar discrepancies have been reported for non-coding RNAs, in which no correlation between the EV-derived and the tissue derived miRNA repertoire, or even an opposite miRNA expression profile in serum versus matched tumor tissues was demonstrated (59,60). Potential reasons include variability in (vesicle-mediated) secretion or passive release of RNA molecules in the bloodstream, differences in the rate and manner of degradation, and the shedding of these markers from other tissues besides the tumor compartment.…”

Section: Discussionsupporting

confidence: 54%

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Decruyenaere,

Giuili,

Verniers

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionDiffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) are aggressive histological subtypes of non-Hodgkin’s lymphoma. Improved understanding of the underlying molecular pathogenesis has led to new classification and risk stratification tools, including the development of cell-free biomarkers through liquid biopsies. The goal of this study was to investigate cell-free RNA (cfRNA) biomarkers in DLBCL and PMBCL patients.Materials and methodsBlood plasma samples (n=168) and matched diagnostic formalin-fixed paraffin-embedded (FFPE) tissue samples (n=69) of DLBCL patients, PMBCL patients and healthy controls were collected between 2016-2021. Plasma samples were collected at diagnosis, at interim evaluation, after treatment, and in case of refractory or relapsed disease. RNA was extracted from 200 µl plasma using the miRNeasy serum/plasma kit and from FFPE tissue using the miRNeasy FFPE kit. RNA was subsequently sequenced on a NovaSeq 6000 instrument using the SMARTer Stranded Total RNA-seq pico v3 library preparation kit.ResultsHigher cfRNA concentrations were demonstrated in lymphoma patients compared to healthy controls. A large number of differentially abundant genes were identified between the cell-free transcriptomes of DLBCL patients, PMBCL patients, and healthy controls. Overlap analyses with matched FFPE samples showed that blood plasma has a unique transcriptomic profile that significantly differs from that of the tumor tissue. As a good concordance between tissue-derived gene expression and the immunohistochemistry Hans algorithm for cell-of-origin (COO) classification was demonstrated in the FFPE samples, but not in the plasma samples, a 64-gene cfRNA classifier was developed that can accurately determine COO in plasma. High plasma levels of a 9-gene signature (BECN1, PRKCB, COPA, TSC22D3, MAP2K3, UQCRHL, PTMAP4, EHD1, NAP1L1 pseudogene) and a 5-gene signature (FTH1P7, PTMAP4, ATF4, FTH1P8, ARMC7) were significantly associated with inferior progression-free and overall survival in DLBCL patients, respectively, independent of the NCCN-IPI score.ConclusionTotal RNA sequencing of blood plasma samples allows the analysis of the cell-free transcriptome in DLBCL and PMBCL patients and demonstrates its unexplored potential in identifying diagnostic, cell-of-origin, and prognostic cfRNA biomarkers.

show abstract

Section: Discussionsupporting

confidence: 54%

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Decruyenaere,

Giuili,

Verniers

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Diverging miR content can be revealing for predicting patient outcomes ( 163 ). Other cargo components were shown to have easily quantifiable differences such as ncRNA species ( 164 ), mRNA ( 165 – 167 ), proteins ( 168 – 171 ) and dsDNA ( 172 ) that could guide the treatment strategy, estimate disease progression ( 173 ), establishing a prognosis ( 174 ), indicate treatment response or even detect minimal residual disease (MRD) ( 174 – 181 ).…”

Section: Evs and Their Contents As Biomarkersmentioning

confidence: 99%

Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment

Van Morckhoven,

Dubois,

Bron

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Following their discovery at the end of the 20th century, extracellular vesicles (EVs) ranging from 50-1,000 nm have proven to be paramount in the progression of many cancers, including hematological malignancies. EVs are a heterogeneous group of cell-derived membranous structures that include small EVs (commonly called exosomes) and large EVs (microparticles). They have been demonstrated to participate in multiple physiological and pathological processes by allowing exchange of biological material (including among others proteins, DNA and RNA) between cells. They are therefore a crucial way of intercellular communication. In this context, malignant cells can release these extracellular vesicles that can influence their microenvironment, induce the formation of a tumorigenic niche, and prepare and establish distant niches facilitating metastasis by significantly impacting the phenotypes of surrounding cells and turning them toward supportive roles. In addition, EVs are also able to manipulate the immune response and to establish an immunosuppressive microenvironment. This in turn allows for ideal conditions for heightened chemoresistance and increased disease burden. Here, we review the latest findings and reports studying the effects and therapeutic potential of extracellular vesicles in various hematological malignancies. The study of extracellular vesicles remains in its infancy; however, rapid advances in the analysis of these vesicles in the context of disease allow us to envision prospects to improve the detection and treatment of hematological malignancies.

show abstract

Research advances in exosomal microRNAs associated with drug resistance in diffuse large B-cell lymphoma

Chen

Dang

Hou

et al. 2023

Asian Journal of Surgery

View full text Add to dashboard Cite

MiR‐22, a serum predictor of poor outcome and therapy response in diffuse large B‐cell lymphoma patients

Cited by 7 publications

References 19 publications

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment

Research advances in exosomal microRNAs associated with drug resistance in diffuse large B-cell lymphoma

Contact Info

Product

Resources

About